CyPath Lung Q2 results
CyPath Lung test volume increased 216% year over year, boosting H1 2026 revenue to $835,000 and bolstering the company's commercial momentum. Bottom-line financials are currently unavailable.
View filing at SEC.gov →2 most recent filings and news items mentioning BIAFW. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/BIAFW/news?limit=20"
Pull BIAFW filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayCyPath Lung test volume increased 216% year over year, boosting H1 2026 revenue to $835,000 and bolstering the company's commercial momentum. Bottom-line financials are currently unavailable.
View filing at SEC.gov →bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth of over 200% to a new record driven by increased physician adoption and repeat utilization. The acceleration in test volume underscores a strong commercial trajectory for the company's non-invasive lung cancer dia
View filing at SEC.gov →